Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 28

1.

Long-term effects of vitamins C and E, β-carotene, and zinc on age-related macular degeneration: AREDS report no. 35.

Chew EY, Clemons TE, Agrón E, Sperduto RD, Sangiovanni JP, Kurinij N, Davis MD; Age-Related Eye Disease Study Research Group.

Ophthalmology. 2013 Aug;120(8):1604-11.e4. doi: 10.1016/j.ophtha.2013.01.021. Epub 2013 Apr 10.

2.

Human phagocyte defect caused by a Rac2 mutation detected by means of neonatal screening for T-cell lymphopenia.

Accetta D, Syverson G, Bonacci B, Reddy S, Bengtson C, Surfus J, Harbeck R, Huttenlocher A, Grossman W, Routes J, Verbsky J.

J Allergy Clin Immunol. 2011 Feb;127(2):535-538.e1-2. doi: 10.1016/j.jaci.2010.10.013. Epub 2010 Dec 16. No abstract available.

PMID:
21167572
3.

An arrayed high-content chemotaxis assay for patient diagnosis.

Berthier E, Surfus J, Verbsky J, Huttenlocher A, Beebe D.

Integr Biol (Camb). 2010 Nov;2(11-12):630-8. doi: 10.1039/c0ib00030b. Epub 2010 Oct 18.

PMID:
20953490
4.

Live imaging of neutrophil motility in a zebrafish model of WHIM syndrome.

Walters KB, Green JM, Surfus JC, Yoo SK, Huttenlocher A.

Blood. 2010 Oct 14;116(15):2803-11. doi: 10.1182/blood-2010-03-276972. Epub 2010 Jun 30.

5.

Calpain inhibition impairs TNF-alpha-mediated neutrophil adhesion, arrest and oxidative burst.

Wiemer AJ, Lokuta MA, Surfus JC, Wernimont SA, Huttenlocher A.

Mol Immunol. 2010 Jan;47(4):894-902. doi: 10.1016/j.molimm.2009.10.002. Epub 2009 Nov 3.

6.

Change in area of geographic atrophy in the Age-Related Eye Disease Study: AREDS report number 26.

Lindblad AS, Lloyd PC, Clemons TE, Gensler GR, Ferris FL 3rd, Klein ML, Armstrong JR; Age-Related Eye Disease Study Research Group.

Arch Ophthalmol. 2009 Sep;127(9):1168-74. doi: 10.1001/archophthalmol.2009.198.

PMID:
19752426
7.

Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients.

King DM, Albertini MR, Schalch H, Hank JA, Gan J, Surfus J, Mahvi D, Schiller JH, Warner T, Kim K, Eickhoff J, Kendra K, Reisfeld R, Gillies SD, Sondel P.

J Clin Oncol. 2004 Nov 15;22(22):4463-73. Epub 2004 Oct 13.

8.

NXS2 murine neuroblastomas express increased levels of MHC class I antigens upon recurrence following NK-dependent immunotherapy.

Neal ZC, Imboden M, Rakhmilevich AL, Kim KM, Hank JA, Surfus J, Dixon JR, Lode HN, Reisfeld RA, Gillies SD, Sondel PM.

Cancer Immunol Immunother. 2004 Jan;53(1):41-52. Epub 2003 Sep 18.

PMID:
14504825
9.

Determination of peak serum levels and immune response to the humanized anti-ganglioside antibody-interleukin-2 immunocytokine.

Hank JA, Surfus JE, Gan J, Ostendorf A, Gillies SD, Sondel PM.

Methods Mol Med. 2003;85:123-31. Review. No abstract available.

PMID:
12710203
10.

Pharmacokinetics and stability of the ch14.18-interleukin-2 fusion protein in mice.

Kendra K, Gan J, Ricci M, Surfus J, Shaker A, Super M, Frost JD, Rakhmilevich A, Hank JA, Gillies SD, Sondel PM.

Cancer Immunol Immunother. 1999 Aug;48(5):219-29.

PMID:
10478638
11.

Distinct clinical and laboratory activity of two recombinant interleukin-2 preparations.

Hank JA, Surfus J, Gan J, Albertini M, Lindstrom M, Schiller JH, Hotton KM, Khorsand M, Sondel PM.

Clin Cancer Res. 1999 Feb;5(2):281-9.

12.

Transcription factor activation in lymphokine activated killer cells and lymphocytes from patients receiving IL-2 immunotherapy.

Nicolet CM, Surfus JM, Hank JA, Sondel PM.

Cancer Immunol Immunother. 1998 Aug;46(6):327-37.

PMID:
9756417
13.
14.

TAG-72-reactive antibody CC49 recognizes molecules expressed by hematopoietic cell lines.

Nicolet CM, Siegel DH, Surfus JE, Sondel PM.

Tumour Biol. 1997;18(6):356-66.

PMID:
9372869
15.

Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2).

Hank JA, Surfus JE, Gan J, Jaeger P, Gillies SD, Reisfeld RA, Sondel PM.

Clin Cancer Res. 1996 Dec;2(12):1951-9.

16.

Systemic interleukin-2 modulates the anti-idiotypic response to chimeric anti-GD2 antibody in patients with melanoma.

Albertini MR, Gan J, Jaeger P, Hank JA, Storer B, Schell K, Rivest T, Surfus J, Reisfeld RA, Schiller JH, Sondel PM.

J Immunother Emphasis Tumor Immunol. 1996 Jul;19(4):278-95.

PMID:
8877722
17.

Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors.

Surfus JE, Hank JA, Oosterwijk E, Welt S, Lindstrom MJ, Albertini MR, Schiller JH, Sondel PM.

J Immunother Emphasis Tumor Immunol. 1996 May;19(3):184-91.

PMID:
8811493
18.

Treatment of neuroblastoma patients with antiganglioside GD2 antibody plus interleukin-2 induces antibody-dependent cellular cytotoxicity against neuroblastoma detected in vitro.

Hank JA, Surfus J, Gan J, Chew TL, Hong R, Tans K, Reisfeld R, Seeger RC, Reynolds CP, Bauer M, et al.

J Immunother Emphasis Tumor Immunol. 1994 Jan;15(1):29-37.

PMID:
8110728
19.

MHC-unrestricted cytotoxic and proliferative responses of two distinct human gamma/delta T cell subsets to Daudi cells.

Fisch P, Oettel K, Fudim N, Surfus JE, Malkovsky M, Sondel PM.

J Immunol. 1992 Apr 15;148(8):2315-23.

PMID:
1532810
20.

Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2.

Hank JA, Robinson RR, Surfus J, Mueller BM, Reisfeld RA, Cheung NK, Sondel PM.

Cancer Res. 1990 Sep 1;50(17):5234-9.

Supplemental Content

Loading ...
Support Center